Evidence map›Paper›PMID 37146029›Full record

ArticlePloS one2023

Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma.

M Lizeth Orozco Morales, Catherine A Rinaldi, Emma de Jong, Sally M Lansley, Y C Gary Lee, Rachael M Zemek, Anthony Bosco, Richard A Lake, W Joost Lesterhuis

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Identification of an episignature for the MEF2C-associated syndrome.European journal of human genetics : EJHG · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

M Lizeth Orozco MoralesSchool of Biomedical Sciences, University of Western Australia, Crawley, Western Australia, Australia.ORCID 0000-0003-0207-0873
Catherine A RinaldiSchool of Biomedical Sciences, University of Western Australia, Crawley, Western Australia, Australia.
Emma de JongTelethon Kids Institute, The University of Western Australia, Nedlands, Western Australia, Australia.
Sally M LansleyInstitute for Respiratory Health, Nedlands, Western Australia, Australia.
Y C Gary LeeInstitute for Respiratory Health, Nedlands, Western Australia, Australia.
Rachael M ZemekTelethon Kids Institute, The University of Western Australia, Nedlands, Western Australia, Australia.ORCID 0000-0002-0976-6163
Anthony BoscoTelethon Kids Institute, The University of Western Australia, Nedlands, Western Australia, Australia.
Richard A LakeSchool of Biomedical Sciences, University of Western Australia, Crawley, Western Australia, Australia.
W Joost LesterhuisSchool of Biomedical Sciences, University of Western Australia, Crawley, Western Australia, Australia.
The Kids Research Institute Australia · AUThe University of Western Australia · AUInstitute for Respiratory Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesothelioma is characterised by its aggressive invasive behaviour, affecting the surrounding tissues of the pleura or peritoneum. We compared an invasive pleural model with a non-invasive subcutaneous model of mesothelioma and performed transcriptomic analyses on the tumour samples. Invasive pleural tumours were characterised by a transcriptomic signature enriched for genes associated with MEF2C and MYOCD signaling, muscle differentiation and myogenesis. Further analysis using the CMap and LINCS databases identified geldanamycin as a potential antagonist of this signature, so we evaluated its potential in vitro and in vivo. Nanomolar concentrations of geldanamycin significantly reduced cell growth, invasion, and migration in vitro. However, administration of geldanamycin in vivo did not result in significant anti-cancer activity. Our findings show that myogenesis and muscle differentiation pathways are upregulated in pleural mesothelioma which may be related to the invasive behaviour. However, geldanamycin as a single agent does not appear to be a viable treatment for mesothelioma.

Indexed as

Lung NeoplasmsMesotheliomaMesothelioma, MalignantPleural NeoplasmsBenzoquinonesCell ProliferationHumansLactams, MacrocyclicBenzoquinonesgeldanamycinLactams, Macrocyclic

Identifiers

PMID37146029
PMCPMC10162533
OpenAlexW4372332791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.